Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Update on typical and atypical antipsychotic drugs.

Meltzer HY.

Annu Rev Med. 2013;64:393-406. doi: 10.1146/annurev-med-050911-161504. Epub 2012 Sep 27. Review.

PMID:
23020880
2.

Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome.

Tandon R, Jibson MD.

Ann Clin Psychiatry. 2002 Jun;14(2):123-9. Review.

3.

What's atypical about atypical antipsychotic drugs?

Meltzer HY.

Curr Opin Pharmacol. 2004 Feb;4(1):53-7.

PMID:
15018839
4.

The role of serotonin receptors in the action of atypical antipsychotic drugs.

Meltzer HY, Massey BW.

Curr Opin Pharmacol. 2011 Feb;11(1):59-67. doi: 10.1016/j.coph.2011.02.007. Epub 2011 Mar 21. Review.

PMID:
21420906
5.

Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients.

Beninger RJ, Baker TW, Florczynski MM, Banasikowski TJ.

Neurotox Res. 2010 Nov;18(3-4):229-43. doi: 10.1007/s12640-010-9178-y. Epub 2010 Apr 8. Review.

PMID:
20376711
6.

Serotonergic mechanisms as targets for existing and novel antipsychotics.

Meltzer HY.

Handb Exp Pharmacol. 2012;(212):87-124. doi: 10.1007/978-3-642-25761-2_4. Review.

PMID:
23129329
7.

Atypical antipsychotics: mechanism of action.

Seeman P.

Can J Psychiatry. 2002 Feb;47(1):27-38. Review.

PMID:
11873706
8.
9.

Serotonin receptors: their key role in drugs to treat schizophrenia.

Meltzer HY, Li Z, Kaneda Y, Ichikawa J.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72. Review.

PMID:
14642974
10.

Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia.

Meltzer HY, Massey BW, Horiguchi M.

Curr Pharm Biotechnol. 2012 Jun;13(8):1572-86. Review.

PMID:
22283753
11.

Atypical antipsychotic agents: a critical review.

Worrel JA, Marken PA, Beckman SE, Ruehter VL.

Am J Health Syst Pharm. 2000 Feb 1;57(3):238-55. Review.

PMID:
10674777
12.

The new antipsychotics. How much better are they?

Keks N, Mazumdar P, Steele K.

Aust Fam Physician. 2000 May;29(5):445-50. Review.

PMID:
10835782
13.

Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function.

Ogino S, Miyamoto S, Miyake N, Yamaguchi N.

Psychiatry Clin Neurosci. 2014 Jan;68(1):37-49. doi: 10.1111/pcn.12088. Epub 2013 Sep 19. Review.

14.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

15.

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders.

J Clin Psychiatry. 2003;64 Suppl 12:5-19.

16.

The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.

Weiner I.

Psychopharmacology (Berl). 2003 Sep;169(3-4):257-97. Epub 2003 Feb 25. Review.

PMID:
12601500
17.
18.

[Atypical antipsychotics in the elderly].

van Melick EJ; Werkgroep Klinische Gerontofarmacologie.

Tijdschr Gerontol Geriatr. 2004 Dec;35(6):240-5. Review. Dutch.

PMID:
15704604
19.

A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia.

Meltzer HY, Bobo WV, Lee MA, Cola P, Jayathilake K.

Psychiatry Res. 2010 May 30;177(3):286-93. doi: 10.1016/j.psychres.2010.02.018. Epub 2010 Apr 8.

PMID:
20378185
20.

Supplemental Content

Support Center